Information to Users

Total Page:16

File Type:pdf, Size:1020Kb

Information to Users INFORMATION TO USERS This manuscript has been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer prfritar. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely event that the author did not send UMI a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginning at the upper left-hand comer and continuing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back of the book. Photographs included in the original manuscript have been reproduced xerographically in this copy. Higher quality 6" x 9" black and white photographic prints are available for any photographs or illustrations appearing in this copy for an additional charge. Contact UMI directly to order. University Microfilms International A Bell & Howell Information Company 300 North Zeeb Road. Ann Arbor. Ml 48106-1346 USA 313/761-4700 800/521-0600 Order Number 9211148 Synthesis and biological results of compounds acting on alpha-adrenergic receptors Hong, Seoung Soo, Ph.D. The Ohio State University, 1991 Copyright ©1991 by Hong, Seoung Soo. All rights reserved. UMI 300 N. Zeeb Rd. Ann Arbor, MI 48106 SYNTHESIS AND BIOLOGICAL RESULTS OF COMPOUNDS ACTING ON ALPHA-ADRENERGIC RECEPTORS DISSERTATION Presented in Partial Fulfillment of the Requirement for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Seoung Soo Hong/ B.S., M.S. * * * * ★ The Ohio State University 1991 Dissertation Committee: Approved by Duane D. Miller, Ph.D. Robert W. Brueggemeier, Ph.D. Larry W. Robertson, Ph.D. Dennis R. Feller, Ph.D. Duane D. Miller, Ph.D., Advisor College of Pharmacy Copyright by Seoung Soo Hong 1991 DEDICATION To my parents, wife, children, and family ii ACKNOWLEDGEMENTS I would like to express my sincere thanks to the following individuals: Dr. Duane D. Miller, my adviser, for his guidance, unending encouragement, and understanding throughout my graduate career, making this dissertation possible. Drs. Dennis R. Feller, Karl J. Romstedt, for the pharmacological data and their help in the interpretation of the data. Carol Settles, for her friendship and greately appreciated assistance throughout my graduate career. The falculty, staff and my fellow graduate students, Ron Hill, Kimberly Markovich, Kazu Matsumoto, for their friendship and support during my graduate study, especially Ron for help preparing this manuscript. Drs. C. George, Judy Flippen-Anderson at the Naval Research Laboratory, for their assistance for X-ray analysis. Dr. Fu-Lian Hsu at the U.S. Army Chemical Research, for his invaluable discussion on the synthesis of medetomidine analogs. Jack Fowble and John Miller, for their assistance in obtaining and interpreting the NMR and mass spectra. Financial supports from U.S. Army CRDEC and the National Institute of Health are gratefully acknowledged. iii VITA August 18, 1955 Born - Taegu, Korea 1981 B.S. Pharmacy, Yeungnam University, Taegu, Korea 1984 M.S. Pharmacy, Yeungnam University, Taegu, Korea 1986 - present Graduate Research Associate, College of Pharmacy, The Ohio State University PUBLICATIONS 1. See-Ryun Chung, Seoung-Soo Hong, and Kyung Hee Jeune- Chung, "Isolation and Purification of Lectin from Phaseolus radiatus", Yakhak Hoeji 1983, 2J_, 221. 2. Yoshia Amemiya, Seoung S. Hong, Burrah V. Venkataraman, Popat N. Patil, Gamal Shams, Karl Romstedt, Dennis R. Feller, Fu-Lian Hsu, and Duane D. Miller, "Synthesis and a-Adrenergic Activities of 2- and 4-Substituted Imidazoline and Imidazole Analogs", J. Med. Chem., in press. 3. S.S. Hong, D.D. Miller, K. Matsumoto, K.L. Romstedt and D.R. Feller, "Synthesis, Isolation, Characterization and a2~Adrenergic Activity of the Optical Isomers of 4-[l-(l- Naphthyl)Ethyl]-1H-Imidazole", Proceedings of the 1991 U.S. Army CRDEC, in press. 4. K. Matsumoto, S.S. Hong, K.L. Romstedt, D.R. Feller and D.D. Miller, "a2-Adrenergic Activity of a New Series of Analogs of 4-[l-(1-Naphthyl)Ethyl]-lH-Imidazole", Proceedings of the 1991 U.S. Army CRDEC, in press. FIELDS OF STUDY Major Field: Pharmacy Studies in Synthetic Medicinal Chemistry v TABLE OF CONTENTS PAGE D e d i c a t i o n ............................................... ii Acknowledgements ....................................... iii VITA .................................................... iv List of Fi g u r e s ...................................... viii List of Tables ........................................ x List of Schemes ........................................ xi CHAPTER I INTRODUCTION ...................................... 1 1.1 The Nervous System ......................... 1 1.2 The Adrenergic Neuronal System ............ 3 1.2.1 Biosynthesis of Catecholamines • • • 4 1.2.2 Catecholamine Storage ............. 6 1.2.3 Catecholamine Release ............. 7 1.2.4 Catecholamine Metabolism and Reuptake ...................... 7 1.3 Subclassification of a-Adrenergic R e c e p t o r s .................................. 11 1.4 Signal Transduction of a-Adrenergic R e c e p t o r s .................................. 24 1.5 Structural Properties of a-Adrenergic Receptors ................... 30 1.6 Structure Activity Relationships of a-Adrenergic Agonists ............... 33 1.7 Structure Activity Relationships of a-Adrenergic Antagonists ........... • 45 1.8 Physiological Functions of a-Adrenergic Agonists and Antagonists • • * 49 II STATEMENT OF PROBLEMS AND OBJECTIVES ............ 53 2.1 Medetomidine Analogs .................... 53 2.2 Phentolamine Analogs .................... 61 Ill RESULTS AND DISCUSSION...........................66 3.1 Chemistry .............................. 66 3.1.1 Synthesis of Naphthalene Analogs of Medetomidine.................. 66 3.1.2 Resolution of 4-[1-(1-naphthyl) ethyl]imidazole enantiomers * • • • 75 3.1.3 Synthesis of Indole Analogs of Medetomidine ................... 82 3.1.4 Synthesis of Phentolamine Analogs • 90 3.2 Biology ................................ 99 3.3 Summary ................................. 107 IV EXPERIMENTAL.................................. 109 BIBLIOGRAPHY ............................................ 154 vii LIST OF FIGURES FIGURE PAGE 1. Subdivision of the nervous system .................. 2 2. Biosynthesis of catecholamines.................... 5 3. Norepinephrine and epinephrine metabolism .......... 9 4. The formation of an aldehyde by M A O ................. 10 5. c^-Adrenoceptor agonists and antagonists .......... 13 6. a2-Adrenoceptor agonists and antagonists.......... 14 7. a2B~Adrenergic receptor selective compounds ........ 22 8. Modern classification of adrenoceptors ............ 24 9. Signal transduction mechanism activated by a^-adrenoceptor ..................................... 26 10. G protein coupled signal transduction .............. 29 11. Signal transduction mechanism activated by presynaptic a2-adrenoceptors ...................... 29 12. Topography of the human a2ft-adrenergic receptor • • • 31 13. Proposed conformation of norepinephrine and clonidine for interaction with a-adrenergic receptors ........................ 35 14. Schematic representation of the Easson-Stedman hypos i s ...............................................36 15. Aromatic ring substituted clonidine-like compounds • 42 16. Imidazoline modified clonidine-like compounds • • • • 44 17. Prazosin derivatives as c^-adrenergic antagonists .......................................... 45 viii 18. Angles between naphthalene, indole rings and a carbon bridge containing imidazole r i n g .................................... 56 19. HPLC chromatogram for the racemic mixture of 4-[1-(1-naphthyl)ethyl]imidazole ............... 79 20. HPLC chromatograms for each enantimer of 4-[l-(1-naphthyl)ethyl]imidazole ................. 80 21. ORTEP representation of (S)-4-[l-(1-naphthyl) ethyl]imidazole .................................... 81 22. Resonance hybrids of indole ....................... 82 23. ORTEP representation of Z-102 ...................... 98. ix LIST OF TABLES TABLE PAGE 1. c^-Adrenergic Receptor Subtype Characteristics • • • 20 2. Differences between Phenethylamines and Imidazolines for Agonist Activity ............... 34 3. Physiological Functions of a-Adrenoceptors ........ 52 4. c^/c^-Selectivity of Medetomidine and its Optical Isomers with Reference Compounds in Rat Brain Membranes ............................. 55 5. Comparison of Medetomidine and its Optical Isomers with Reference Compounds in Mouse vas deferens ............................. 58 6. Functional Groups used as Isosteric Replacements* • 63 7. Comparison of Adrenergic Activities of Medetomidine (51) and Analog S4 in Rat Aorta and Human Platelets .....................100 8. Inhibition of Epinephrine-Induced Human Platelet Aggregation by Compounds j54, S(+)-52, and R( -) -57 • 102 9. Comparison of Adrenergic Activities of Compounds 54, R(-)-57, S(+)-57, and Reference Compounds .............................. 103 10. Inhibition of Epinephrine-Induced Human Platelet
Recommended publications
  • ALPHA ADRENOCEPTORS and HUMAN SEXUAL FUNCTION Alan
    8 1995 Elsevier Science B. V. All rights reserved. The Pharmacology of Sexual Function and Dysfunction J. Bancroft, editor 307 ALPHA ADRENOCEPTORS AND HUMAN SEXUAL FUNCTION Alan J Riley Field Place, Dunsmore, Buckinghamshire, HP22 6QH, UK Introduction Sexual functioning involves complex physiological processes which rely on the interplay of many central and peripheral neurotransmitter systems. Disturbances in any one of these systems might be associated with disturbed sexual function which, when recognised, may be alleviated by appropriate pharmacological manipulation, although at the present time this is more hypothesis than reality, The sympathetic nervous system is involved actively at various levels in the normal control of sexual responses. The effects of sympathetic activation are mediated by the release of noradrenaline from nerve terminals and the increased secretion of adrenaline from the adrenal medulla. These catecholamines selectively activate specific cellular sites in target tissues known as adrenoceptors (previously termed adrenergic receptors) to mediate responses. Almost fifty years ago, Alquist realised that tissue responses to catecholamines were mediated through two distinct types of receptors which he designated a and/? [1]. This review focuses on the involvement of a-adrenoceptors in human sexual functioning and dysfunction. Alpha adrenoceptors are located both pre- and post- synaptically and they were classified as either ar or af adrenoceptors according to location; or, being postsynaptic and az presynaptic. This classification continues to be used in some texts. However, as highly specific and selective pharmacological tools became available, this locational subclassification is found not always to be appropriate. Nowadays, classification of a-adrenoceptors is more appropriately based on pharmacological activity and additional subtypes of a-adrenoceptors have been identified by radioligand binding and molecular biological techniques [2].
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Piperidine Derivatives Piperidinderivate Derives De Piperidine
    (19) TZZ_¥Z_T (11) EP 1 669 350 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 211/58 (2006.01) C07D 401/06 (2006.01) 29.02.2012 Bulletin 2012/09 C07D 401/14 (2006.01) C07D 401/02 (2006.01) C07D 401/12 (2006.01) C07D 409/12 (2006.01) (2006.01) (2006.01) (21) Application number: 04787951.5 A61K 31/4545 A61K 31/496 A61K 31/454 (2006.01) A61K 31/4523 (2006.01) A61K 31/4535 (2006.01) A61K 31/506 (2006.01) (22) Date of filing: 21.09.2004 A61P 43/00 (2006.01) A61P 3/04 (2006.01) A61P 3/10 (2006.01) A61P 5/00 (2006.01) A61P 3/06 (2006.01) A61P 19/06 (2006.01) A61P 9/10 (2006.01) A61P 9/04 (2006.01) A61P 9/12 (2006.01) (86) International application number: PCT/JP2004/013768 (87) International publication number: WO 2005/028438 (31.03.2005 Gazette 2005/13) (54) PIPERIDINE DERIVATIVES PIPERIDINDERIVATE DERIVES DE PIPERIDINE (84) Designated Contracting States: • TOKITA, Shigeru, AT BE BG CH CY CZ DE DK EE ES FI FR GB GR c/o Tsukuba Research Institute HU IE IT LI LU MC NL PL PT RO SE SI SK TR Tsukuba-shi, Designated Extension States: Ibaraki 3002611 (JP) LT LV • KANATANI, Akio, c/o Tsukuba Research Institute (30) Priority: 22.09.2003 JP 2003330758 Tsukuba-shi, Ibaraki 3002611 (JP) (43) Date of publication of application: 14.06.2006 Bulletin 2006/24 (74) Representative: Rollins, Anthony John et al Merck Sharp & Dohme Limited (73) Proprietor: MSD K.K.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7.803,838 B2 Davis Et Al
    USOO7803838B2 (12) United States Patent (10) Patent No.: US 7.803,838 B2 Davis et al. (45) Date of Patent: Sep. 28, 2010 (54) COMPOSITIONS COMPRISING NEBIVOLOL 2002fO169134 A1 11/2002 Davis 2002/0177586 A1 11/2002 Egan et al. (75) Inventors: Eric Davis, Morgantown, WV (US); 2002/0183305 A1 12/2002 Davis et al. John O'Donnell, Morgantown, WV 2002/0183317 A1 12/2002 Wagle et al. (US); Peter Bottini, Morgantown, WV 2002/0183365 A1 12/2002 Wagle et al. (US) 2002/0192203 A1 12, 2002 Cho 2003, OOO4194 A1 1, 2003 Gall (73) Assignee: Forest Laboratories Holdings Limited 2003, OO13699 A1 1/2003 Davis et al. (BM) 2003/0027820 A1 2, 2003 Gall (*) Notice: Subject to any disclaimer, the term of this 2003.0053981 A1 3/2003 Davis et al. patent is extended or adjusted under 35 2003, OO60489 A1 3/2003 Buckingham U.S.C. 154(b) by 455 days. 2003, OO69221 A1 4/2003 Kosoglou et al. 2003/0078190 A1* 4/2003 Weinberg ...................... 514f1 (21) Appl. No.: 11/141,235 2003/0078517 A1 4/2003 Kensey 2003/01 19428 A1 6/2003 Davis et al. (22) Filed: May 31, 2005 2003/01 19757 A1 6/2003 Davis 2003/01 19796 A1 6/2003 Strony (65) Prior Publication Data 2003.01.19808 A1 6/2003 LeBeaut et al. US 2005/027281.0 A1 Dec. 8, 2005 2003.01.19809 A1 6/2003 Davis 2003,0162824 A1 8, 2003 Krul Related U.S. Application Data 2003/0175344 A1 9, 2003 Waldet al. (60) Provisional application No. 60/577,423, filed on Jun.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin Et Al
    US 201201.15729A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin et al. (43) Pub. Date: May 10, 2012 (54) PROCESS FOR FORMING FILMS, FIBERS, Publication Classification AND BEADS FROM CHITNOUS BOMASS (51) Int. Cl (75) Inventors: Ying Qin, Tuscaloosa, AL (US); AOIN 25/00 (2006.01) Robin D. Rogers, Tuscaloosa, AL A6II 47/36 (2006.01) AL(US); (US) Daniel T. Daly, Tuscaloosa, tish 9.8 (2006.01)C (52) U.S. Cl. ............ 504/358:536/20: 514/777; 426/658 (73) Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF 57 ABSTRACT ALABAMA, Tuscaloosa, AL (US) (57) Disclosed is a process for forming films, fibers, and beads (21) Appl. No.: 13/375,245 comprising a chitinous mass, for example, chitin, chitosan obtained from one or more biomasses. The disclosed process (22) PCT Filed: Jun. 1, 2010 can be used to prepare films, fibers, and beads comprising only polymers, i.e., chitin, obtained from a suitable biomass, (86). PCT No.: PCT/US 10/36904 or the films, fibers, and beads can comprise a mixture of polymers obtained from a suitable biomass and a naturally S3712). (4) (c)(1), Date: Jan. 26, 2012 occurring and/or synthetic polymer. Disclosed herein are the (2), (4) Date: an. AO. films, fibers, and beads obtained from the disclosed process. O O This Abstract is presented solely to aid in searching the sub Related U.S. Application Data ject matter disclosed herein and is not intended to define, (60)60) Provisional applicationpp No. 61/182,833,sy- - - s filed on Jun.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • Antihypertensive Agents Using ALZET Osmotic Pumps
    ALZET® Bibliography References on the Administration of Antihypertensive Agents Using ALZET Osmotic Pumps 1. Atenolol Q7652: W. B. Zhao, et al. Stimulation of beta-adrenoceptors up-regulates cardiac expression of galectin-3 and BIM through the Hippo signalling pathway. British Journal of Pharmacology 2019;176(14):2465-2481 Agents: Isoproterenol; propranolol; carvedilol; atenolol; ICI-118551 Vehicle: saline; ascorbic acid, buffered; Route: SC; Species: Mice; Pump: 2001; Duration: 1 day; 2 days; 7 days; ALZET Comments: Dose ((ISO 0.6, 6, 20 mg/kg/d), (Prop 2 mg/kg/d), (Carv 2 mg/kg/d), (AT 2 mg/kg/d), (ICI 1 mg/kg/d)); saline with 0.4 mM ascorbic acid used; Controls were non-transgenic and received mp w/ vehicle; animal info (12-16 weeks, Male, (C57BL/6J, beta2-TG, Mst1-TG, or dnMst1-TG)); ICI-118551 is a beta2-antagonist with the structure (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; cardiovascular; Minipumps were removed to allow for washout of ISO overnight prior to imaging; Q7241: M. N. Nguyen, et al. Mechanisms responsible for increased circulating levels of galectin-3 in cardiomyopathy and heart failure. Sci Rep 2018;8(1):8213 Agents: Isoproterenol, Atenolol, ICI-118551 Vehicle: Saline, ascorbic acid; Route: SC; Species: Mice; Pump: Not Stated; Duration: 48 Hours; ALZET Comments: Dose: ISO (2, 6 or 30 mg/kg/day; atenolol (2 mg/kg/day), ICI-118551 (1 mg/kg/day); 0.4 mM ascorbic used; animal info (12 14 week-old C57Bl/6 mice); cardiovascular; Q6161: C.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2005/0049256A1 Lorton Et Al
    US 2005.0049256A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0049256A1 LOrton et al. (43) Pub. Date: Mar. 3, 2005 (54) TREATMENT OF INFLAMMATORY Publication Classification AUTOIMMUNE DISEASES WITH ALPHA-ADRENERGIC ANTAGONSTS AND BETA-ADRENERGICAGONSTS (51) Int. Cl." ...................... A61K 31/517; A61K 31/137 (76) Inventors: Dianne Lorton, Avondale, AZ (US); (52) U.S. Cl. ..................... 514/252.17; 514/649; 514/651 Cheri Lubahn, Glendale, AZ (US) Correspondence Address: JENNINGS, STROUSS & SALMON, P.L.C. (57) ABSTRACT 201 E. WASHINGTON ST, 11TH FLOOR PHOENIX, AZ 85004 (US) The present invention discloses a novel compound and (21) Appl. No.: 10/928,437 method for the treatment of inflammatory autoimmune dis eases, for example, rheumatoid arthritis, using C.-adrenergic (22) Filed: Aug. 27, 2004 antagonists and B-adrenergic agonists in combination. Treat ment of animals, namely humans, with an O-adrenergic Related U.S. Application Data antagonist, preferably, phentolamine, and a B-adrenergic agonist, preferably terbutaline, in combination can Signifi (60) Provisional application No. 60/498.367, filed on Aug. cantly Suppress the joint destruction and inflammation due to 27, 2003. disease in these animals. Patent Application Publication Mar. 3, 2005 Sheet 1 of 5 US 2005/0049256A1 Patent Application Publication Mar. 3, 2005 Sheet 2 of 5 US 2005/0049256A1 e \ s o o (ulu) pA ped)00 IBuedos. IOC Patent Application Publication Mar. 3, 2005 Sheet 3 of 5 US 2005/0049256A1 as o N w N o et N O CY) c5 O t al L cN Y D. a s t is r s re y (uu) supW pedoo Patent Application Publication US 2005/004925.6 A1 |0*>d 0|| eIOOS 3 guide foupe Patent Application Publication Mar.
    [Show full text]
  • A2) United States Patent (0) Patent No.: US 9,078,919 B2 Olsonet Al
    US009078919B2 a2) United States Patent (0) Patent No.: US 9,078,919 B2 Olsonet al. (45) Date of Patent: *Jul. 14, 2015 (54) MICRO-RNAS OF THE MIR-15 FAMILY 2005/0182011 Al 8/2005 Olson etal. MODULATE CARDIOMYOCYTE SURVIVAL 2006/0058266 Al 3/2006 Manoharan etal. AND CARDIAC REPAIR 2006/0105360 Al 5/2006 Croce etal. 2006/0165659 Al 7/2006 Croceet al. 2006/0185027 Al 8/2006 Bartelet al. (71) Applicant: The Board of Regents, The University 2006/0189557 Al 8/2006 Slack et al. of Texas System, Austin, TX (US) 2006/0247193 Al 11/2006 Taira et al. 2006/0252722 Al 11/2006 Lollo et al. (72) Inventors: Eric N. Olson, Dallas, TX (US); Eva 2007/0026403 Al 2/2007 Hatzigeorgiouetal. 2007/0054287 Al 3/2007 Bloch van Rooij, Utrecht (NL) 2007/0213292 Al 9/2007 Stoffel et al. 2007/0259827 Al 11/2007 Aronin et al. (73) Assignee: The Board of Regents, the University 2007/0287179 Al 12/2007 Tuschletal. of Texas System, Austin, TX (US) 2007/0292878 Al 12/2007 Raymond. 2008/0050744 Al 2/2008 Brownetal. (*) Notice: Subject to any disclaimer, the term of this 2008/0176766 Al 7/2008 Brownetal. 2008/0220423 Al 9/2008 Molleret al. patent is extended or adjusted under 35 2009/0053718 Al 2/2009 Naguibnevaetal. U.S.C. 154(b) by 0 days. 2009/0092980 Al 4/2009 Arenzet al. 2009/0131356 Al 5/2009 Baderet al. This patent is subject to a terminal dis- 2009/0176723 Al 7/2009 Brownetal. claimer. 2009/0214477 Al 8/2009 Betzet al.
    [Show full text]